Research programme: VEGF inhibitors - Interprotein

Drug Profile

Research programme: VEGF inhibitors - Interprotein

Latest Information Update: 08 Dec 2013

Price : $50

At a glance

  • Originator Interprotein Corporation
  • Class Antibodies; Peptides; Small molecules
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 26 Nov 2013 Early research is ongoing in Japan
  • 21 Nov 2008 Early research in Solid tumours in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top